Stocks On the Move: iRobot Corporation, Regulus Therapeutics Inc, and Tekmira Pharmaceuticals Corporation

IRBT, RGLS, and TKMR are moving sharply in Wednesday's trading

Oct 22, 2014 at 11:25 AM
facebook twitter linkedin


U.S. stocks are modestly higher this morning, as Wall Street digests stimulus news out of Europe, a slight uptick in consumer prices, and the latest round of earnings reports. Among the names making significant moves are artificial intelligence issue iRobot Corporation (NASDAQ:IRBT), as well as drugmakers Regulus Therapeutics Inc (NASDAQ:RGLS) and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). Here's a quick look at how IRBT, RGLS, and TKMR are faring on the charts today.

  • IRBT is 16.6% higher at $36.87, after the firm said third-quarter profit nearly doubled from the year-ago period, topping analysts' expectations. The shares of iRobot Corporation are now 5.3% higher year-to-date, and on pace to end the week atop their 10-week and 20-week moving averages for the first time since early July. J.P. Morgan Securities chimed in by upping its price target to $38 from $36.50, though the brokerage firm upheld a lukewarm "neutral" rating. Elsewhere, short sellers could be hitting the bricks. Short interest accounts for more than a quarter of IRBT's total available float, representing nearly nine sessions' worth of pent-up buying demand, at the stock's average pace of trading.

  • RGLS is hands-down the biggest advancer on the Nasdaq thus far, after the firm announced encouraging data regarding its proposed hepatitis C treatment. The stock was last seen 84.6% higher at $12.50, and earlier peaked at a record high of $15 -- more than twice the stock's closing price of $6.77 yesterday. As with IRBT, Regulus Therapeutics Inc shares are likely enjoying a short squeeze, as short interest accounts for 8.1% of the equity's available float. In fact, it would take more than three weeks to buy back all of these bearish bets, at RGLS' average daily trading volume.

  • TKMR is flirting with $19.69, up 9.8%, after the company said it's started limited manufacturing of an Ebola treatment, which should be available by early December. On the charts, TKMR has skyrocketed 147% year-to-date, but since grazing the $30 level earlier this month, has dropped to test support at its 80-day moving average. Most analysts are already in the bulls' camp, with four out of six offering up "buy" or better endorsements, and not a single "sell" in sight. Plus, the consensus 12-month price target of $36.50 stands in uncharted territory for Tekmira Pharmaceuticals Corporation, and represents expected upside of more than 85% to the stock's current price.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners